Pharmaceutical industry
Despite a stronger-than-expected jobs report that boosted chances of the Federal Reserve's rate liftoff, the major averages closed the first week of November with gains, continuing the momentum seen throughout October. The jobs report showed nonfarm payrolls growing by 271,000 jobs in October, exceeding expectations of 185,
Pharmaceutical industry
Pharmaceutical companies are facing increased scrutiny and criticism from politicians, regulators, and patients over rapidly rising drug prices. This week, a bipartisan Senate investigation was announced to explore the issue, and a trade group representing dozens of drug companies, the Pharmaceutical Research and Manufacturers of America (PhRMA), is pushing back,
Pharmaceutical industry
Current research results suggest that the anti-cancer drugs sunitinib and imatinib may have unintended effects on the heart, potentially contributing to cardiac dysfunction. A study published in the British Journal of Pharmacology found that chronic administration of these drugs increased the expression and activity of calcium/calmodulin-dependent protein kinase II
Pharmaceutical industry
The US Food and Drug Administration (FDA) has granted approval for a new 60 mg dose of AstraZeneca's blood thinner Brilinta, which can be used by patients beyond the first year to prevent blood clots that can cause heart attacks, strokes, and deaths. This approval is expected to
Pharmaceutical industry
As of Thursday, September 3, 2015, the Health Care sector is showing signs of resilience despite initial declines, driven by strong performances from key players like HCA Holdings, Express Scripts, and Aetna. The sector currently sits down 0.4% versus the S&P 500, which is up 0.5%
Pharmaceutical industry
AstraZeneca, Sanofi, and Eli Lilly are among the top performers in the Drugs industry, with shares of each company trading higher today. Despite some negative performers within the industry, including Catalent, Alnylam Pharmaceuticals, and Perrigo, these three stocks are helping to drive the industry's upward momentum. TheStreet Ratings
Pharmaceutical industry
Nektar Therapeutics, a biopharmaceutical company, and The University of Texas MD Anderson Cancer Center have announced a research collaboration to evaluate the safety and efficacy of NKTR-214, a CD122-biased immune-stimulatory cytokine, in patients with various types of cancer. The collaboration includes a Phase 1/2 clinical study to evaluate NKTR-214
Pharmaceutical industry
The pharmaceutical companies Eli Lilly and Company and AstraZeneca have announced the launch of a clinical trial collaboration to evaluate the safety and preliminary efficacy of MEDI4736 in combination with CYRAMZA for advanced solid tumors. The partnership will see AstraZeneca evaluate the combination of MEDI4736, an investigational anti-PD-L1 immune checkpoint
Pharmaceutical industry
Researchers at AstraZeneca have developed a highly sensitive and specific droplet digital PCR method for detecting EGFR-activating mutations in plasma cell-free DNA from patients with non-small cell lung cancer. This innovative approach has the potential to revolutionize clinical blood testing for lung cancer diagnosis. According to the study, the new
Pharmaceutical industry
A recent study involving 57,946 patients with type 2 diabetes has found that diabetes and chronic kidney disease (CKD) are independent predictors of death and cardiovascular events. The study, conducted by AstraZeneca, aimed to characterize the effect of estimated glomerular filtration rate (eGFR) and other factors on the risk
Pharmaceutical industry
Medco Health Solutions Inc., a wholly-owned subsidiary of Express Scripts Holding Company, has agreed to pay $7.9 million to settle allegations that it engaged in a kickback scheme with pharmaceutical manufacturer AstraZeneca in violation of the False Claims Act. The scheme involved Medco soliciting remuneration from AstraZeneca in exchange
Pharmaceutical industry
The US Food and Drug Administration (FDA) has issued a warning regarding a class of type 2 diabetes drugs sold by several major pharmaceutical companies. The warning highlights the potential risk of dangerously high levels of blood acids in patients taking these medications. The oral drugs, known as SGLT2 inhibitors,
